Endocrine-inactive pituitary tumors: pathology and current approaches to diagnosis and treatment
https://doi.org/10.14412/2074-2711-2023-4-89-93
Abstract
pathological hormone secretion, the clinical presentation is determined by the localization of the tumor. Common symptoms include headache and visual field defects. This review addresses the pathology aspects of diagnosis, conservative treatment, and methods of radiation therapy. Drug therapy of endocrine-inactive adenomas is based on the presence of receptors for somatostatin and dopamine in pituitary adenoma cells. Data on stereotactic radiosurgery techniques such as gamma and cyberknife and disease prognosis are presented.
About the Authors
V. N. Nikolenko
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Lomonosov Moscow State University
Russian Federation
Russian Federation
119991, Москва, ул. Трубецкая, 8, стр. 2
119991, Москва, Ленинские горы, 1
B. A. Volel
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
119991, Москва, ул. Трубецкая, 8, стр. 2
A. N. Shkarubo
Burdenko National Medical Research Center for Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16, 4th Tverskaya-Yamskaya St., Moscow 125047
A. A. Nagajtseva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
119991, Москва, ул. Трубецкая, 8, стр. 2
T. S. Zharikova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Lomonosov Moscow State University
Russian Federation
Russian Federation
Tatyana Sergeevna Zharikova
119991, Москва, ул. Трубецкая, 8, стр. 2
119991, Москва, Ленинские горы, 1
Yu. O. Zharikov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
119991, Москва, ул. Трубецкая, 8, стр. 2
References
1. Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary. 2018;21(2):111-8. doi: 10.1007/S11102-018-0869-3
2. Zatelli MC. Pathogenesis of non-functioning pituitary adenomas. Pituitary. 2018;21(2):130-7. doi: 10.1007/S11102-018-0874-6
3. Rizzoli P, Iuliano Sh, Weizenbaum E, Laws E. Headache in Patients With Pituitary Lesions: A Longitudinal Cohort Study. Neurosurgery. 2016;78(3):316-23. doi: 10.1227/NEU.0000000000001067
4. Barkhoudarian G, Kelly DF. Pituitary Apoplexy. Neurosurg Clin N Am. 2019 Oct;30(4):457-63. doi: 10.1016/j.nec.2019.06.001. Epub 2019 Aug 7.
5. Monteiro DM, Freitas P, Vieira R, Carvalho D. Hypogonadotropic hypogonadism in non-functioning pituitary adenomas: impact of intervention. Exp Clin Endocrinol Diabetes. 2017;125(6):368-76. doi: 10.1055/s-0042-124355
6. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas. JAMA. 2017 Feb 7;317(5):516-24. doi: 10.1001/jama.2016.19699
7. Esposito D, Olsson DS, Ragnarsson O, et al. Non_functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary. 2019 Aug;22(4):422-34. doi: 10.1007/s11102-019-00960-0
8. Huang W, Molitch ME. Management of nonfunctioning pituitary adenomas (NFAs): observation. Pituitary. 2018;21(2):162-7. doi: 10.1007/s11102-017-0856-0
9. Penn DL, Burke WT, Laws ER. Management of non-functioning pituitary adenomas: surgery. Pituitary. 2018;21:145-53. doi: 10.1007/s11102-017-0854-2
10. AlMalki MH, Ahmad MM, Brema I, et al. Contemporary Management of Clinically Non- functioning Pituitary Adenomas: A Clinical Review. Clin Med Insights Endocrinol Diabetes. 2020 Jun 24;13:1179551420932921. doi: 10.1177/1179551420932921
11. Kalinin PL, Kadashev BA, Fomichev DV, et al. Surgical treatment for pituitary adenomas. Voprosy neirokhirurgii = Burdenko's Journal of Neurosurgery. 2017;81(1):95-107. doi: 10.17116/neiro201780795-107 (In Russ.)].
12. Grigor'ev AYu, Ivashchenko OV, Nadezhdina EYu. The main principles of hemostasis in endoscopic transnasal surgery of chiasmatic mass lesions. Neirokhirurgiia = Russian Journal of Neurosurgery. 2017;(4):3-10 (In Russ.)].
13. Shkarubo AN. Atlas endoskopicheskoy endonazal'noy khirurgii osnovaniya cherepa i kraniovertebral'nogo sochleneniya [Atlas of endoscopic endonasal surgery of the skull base and craniovertebral joint]. Moscow: ABV-press; 2020. 272 p. (In Russ.)].
14. Eseonu CI, ReFaey K, Rincon-Torroella J,et al. Endoscopic Versus Microscopic Transsphenoidal Approach for Pituitary Adenomas: Comparison of Outcomes During the Transition of Methods of a Single Surgeon. World Neurosurg. 2017 Jan;97:317-25. doi: 10.1016/j.wneu.2016.09.120. Epub 2016 Oct 11.
15. Popova TN, Nikolenko VN, Zhandarova LF, et al. Onkologiya: Uchebnoye posobiye dlya studentov vysshikh uchebnykh zavedeniy [Oncology: Textbook for students of higher educational institutions]. Ed. P.V. Glybochko. Moscow: Publishing Center “Academy”; 2008. 400 p. (In Russ.)].
16. Forster N, Warnick R, Takiar V, et al.Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery. J Neurooncol. 2018 Jun;138(2):335-40. doi: 10.1007/s11060-0182801-0. Epub 2018 Feb 15.
17. Kessel KA, Diehl CD, Oechsner M, et al.Patient-reported outcome (PRO) as an addition to long-term results after high-precision stereotactic radiotherapy in patients with secreting and non-secreting pituitary adenomas: a retrospective cohort study up to 17-years follow-up. Cancers. 2019;11(12):1884. doi: 10.3390/cancers11121884
18. Narayan V, Mohammed N, Bir SC, et al.Long-Term Outcome of Nonfunctioning and Hormonal Active Pituitary Adenoma After Gamma Knife Radiosurgery. World Neurosurg. 2018;114:e824-e832. doi: 10.1016/j.wneu.2018.03.094
19. Yu J, Li Y, Quan T, et al. Initial GammaKnife radiosurgery for nonfunctioning pituitary adenomas: results from a 26-year experience. Endocrine. 2020;68:399-410. doi: 10.1007/s12020-020-02260-1
20. Ding C, Saw CB, Timmerman RD. Cyberknife stereotactic radiosurgery and radiation therapy treatment planning system. Med Dosim. 2018 Summer;43(2):129-40. doi: 10.1016/j.meddos.2018.02.006. Epub 2018 Mar 28.
21. Minniti G, Flickinger J, Tolu B, Paolini S.Management of nonfunctioning pituitary tumors: radiotherapy. Pituitary. 2018;21(2):154-61. doi: 10.1007/S11102-018-0868-4
22. Minniti G, Clarke E, Scaringi C, Enrici RM.Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother. 2016;21(4):370-8. doi: 10.1016/j.rpor.2014.09.004
23. Kotecha R, Sahgal A, Rubens M, et al.Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion. Neuro Oncol. 2020 Mar 5;22(3):318-32. doi: 10.1093/neuonc/noz225
24. Chanson Ph, Dormoy A, Dekkers OM. Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol. 2019;181(1):D1-D13. doi: 10.1530/EJE-19-0058
25. Yamanaka R, Abe E, Sato T, et al. Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review. Cancers (Basel). 2017;9(8):103. doi: 10.3390/cancers9080103
26. Eremkina AK, Dzeranova LK, Pigarova EK, et al. Morphofunctional features of non-functioning pituitary adenomas. Arkhiv patologii = Archive of Pathology. 2019;81(1):71-8. doi: 10.17116/patol20198101171 (In Russ.)].
27. Delgado-Lopez PD, Pi-Barrio J, Duenas-Polo MT, et al. Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options. Clin Transl Oncol. 2018 Oct;20(10):1233-45. doi: 10.1007/s12094018-1868-6. Epub 2018 Apr 5.
28. Batista RL, Musolino NRC, Cescato VAS,et al. Cabergoline in the management of residual nonfunctioning pituitary adenoma. Am J Clin Oncol. 2019;42(2):221-7. doi: 10.1097/COC.0000000000000505
29. Mercado M, Melgar V, Salame L, Cuenca D. Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and therapeutic aspects. Endocrinol Diabetes Nutr. 2017;64(7):384-95. doi: 10.1016/j.endinu.2017.05.009
30. Tampourlou M, Karapanou O, Vassiliadi DA, Tsagarakis S. Medical therapy for non-functioning pituitary tumors – a critical approach. Hormones (Athens). 2019;18(2):117-26. doi: 10.1007/s42000-018-0070-0
31. Tampourlou M, Fountas A, Ntali G,Karavitaki N. Mortality in patients with nonfunctioning pituitary adenoma. Pituitary. 2018;21(2):203-7. doi: 10.1007/s11102-018-0863-9
32. Andino-Rios GG, Portocarrero-Ortiz L,Rojas-Guerrero C, et al. Nonfunctioning Pituitary Adenoma That Changed to a Functional Gonadotropinoma. Case Rep Endocrinol. 2018 Apr 29;2018:5027859. doi: 10.1155/2018/5027859
Review
For citations:
Nikolenko V.N., Volel B.A., Shkarubo A.N., Nagajtseva A.A., Zharikova T.S., Zharikov Yu.O. Endocrine-inactive pituitary tumors: pathology and current approaches to diagnosis and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):89-93. (In Russ.) https://doi.org/10.14412/2074-2711-2023-4-89-93
Views: 50
Email this article 